VJHemOnc – Video Journal of Hematology & HemOnc

Acquired von Willebrand disease in Waldenström’s macroglobulinemia: diagnosis and treatment

Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia

WM-NET: upcoming clinical trials to advance the treatment of WM

Multi-omic analysis in WM: progress being made and challenges that remain

A Phase II study investigating epcoritamab in the treatment of Waldenström’s macroglobulinemia

The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53

The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM

Multi-omics studies to understand the progression from premalignant states to WM

Hyperviscosity syndrome as a complication in WM and its management with plasma exchange

Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenström's macroglobulinemia

The diverse presentation of symptoms in patients with Waldenström's macroglobulinemia

The role of the microenvironment and stromal components in WM progression and drug resistance

Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM

Lymphoma highlights from ASH 2021

The value of using next-generation flow cytometry to measure MRD status

The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL

The complications of treating elderly patients with AML

Key myeloma discussion topics at LLM 2021

The application of AI in healthcare and in clinical practice

Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL

CITADEL-204: parsaclisib in R/R MZL

What impact do side effects have on elderly chronic myeloid leukemia (CML) patients?

Single-cell transcriptomic analysis of B-ALL: leukemia cell state and genetic alterations

Emerging treatment options for MZL

CITADEL-204: safety and efficacy of parsaclisib in R/R MZL

ALL and CLL updates at ASCO 2021

The challenges of treating older patients with Hodgkin lymphoma

Phase 1 trials of novel CAR T-cells for leukemia

Cellular and targeted therapies for Hodgkin lymphoma

MAGNOLIA trial: zanubrutinib for MZL

The evolution of treatment for elderly patients with CLL

RELEVANCE: Rituximab and lenalidomide in FL

The changing landscape of BTK inhibitor therapy in patients with MZL

Current status of third-line therapy for CML

The role of NK cells in preventing relapse in leukemia

CAR-T therapy, a novel promising treatment option for chronic hepatitis B and HBV-associated HCC

Updates on cellular and molecular interactions in the CLL microenvironment

Risk of transformation by frontline management in FL and MZL: a US population-based analysis

Cost-effectiveness of 12-month VenG for CLL

A study of dizygotic twins with JAK2-positive MPNs

JAK2 V617F VAF as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk

Types of histiocytosis and their treatment strategies

The benefits and drawbacks of cord blood transplantation

Current status of alloHSCT in BP-MPNs

Current treatment approaches in extranodal MZL & the need to enhance prognostication strategies

Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study

The role of the tumor microenvironment in splenic MZL: T-reg expression

Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphoma

Is endothelial protection effective for GVHD, VOD and TMA?

Pirtobrutinib in R/R MZL: insights from the BRUIN trial

Novel agents in MZL: BTKis, PI3K inhibitors, and immunotherapeutics